

Study Number: I10482
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 11/04/2020
Time Report Requested: 14:06:22
Lab: Burleson Research Technologies

Study Number: I10482
Study Gender: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.0.9

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/04/2020

Time Report Requested: 14:06:22

Lab: Burleson Research Technologies

Females: Immunopath							
Treatment Groups (ppm)							
	0	313	625	1250	2500	5000	50 mg/kg CPS
Leukocytes (10 ³ /μl)	6.319 ± 0.599 (8)	5.411 ± 0.469 (8)	5.655 ± 0.497 (8)	5.423 ± 0.553 (8)	6.391 ± 0.481 (8)	4.500 ± 0.095 (8)	1.689 ± 0.207 (8) *
Lymphocytes (10 ³ /μl)	5.089 ± 0.520 (8)	4.440 ± 0.380 (8)	4.686 ± 0.441 (8)	4.446 ± 0.465 (8)	5.321 ± 0.377 (8)	3.686 ± 0.055 (8)	1.458 ± 0.170 (8) *
Neutrophils (10 ³ /μl)	0.881 ± 0.105 (8)	0.694 ± 0.076 (8)	0.698 ± 0.044 (8)	0.684 ± 0.077 (8)	0.698 ± 0.074 (8)	0.618 ± 0.054 (8)	0.140 ± 0.024 (8) *
Monocytes (10 ³ /μl)	0.089 ± 0.009 (8)	0.100 ± 0.020 (8)	0.065 ± 0.011 (8)	0.068 ± 0.008 (8)	0.096 ± 0.014 (8)	0.069 ± 0.007 (8)	0.015 ± 0.003 (8) *
Eosinophils (10 ³ /μl)	0.148 ± 0.020 (8)	0.094 ± 0.014 (8)	0.109 ± 0.017 (8)	0.131 ± 0.030 (8)	0.176 ± 0.065 (8)	0.079 ± 0.015 (8) *	0.045 ± 0.022 (8) *
Basophils (10 ³ /μl)	0.034 ± 0.003 (8)	0.034 ± 0.010 (8)	0.035 ± 0.008 (8)	0.038 ± 0.006 (8)	0.034 ± 0.006 (8)	0.019 ± 0.003 (8)	0.006 ± 0.003 (8) *
Large Unstained Cells (10 ³ /μl)	0.078 ± 0.010 (8) **	0.048 ± 0.013 (8)	0.063 ± 0.018 (8)	0.056 ± 0.013 (8)	0.070 ± 0.026 (8)	0.033 ± 0.005 (8) **	0.024 ± 0.010 (8) *
Percent Lymphocytes	80.19 ± 1.20 (8)	82.19 ± 0.73 (8)	82.63 ± 0.77 (8)	81.90 ± 0.76 (8)	83.43 ± 0.97 (8)	82.05 ± 1.18 (8)	86.75 ± 1.27 (8) *
Percent Neutrophils	14.19 ± 1.15 (8)	12.73 ± 0.52 (8)	12.59 ± 0.61 (8)	12.60 ± 0.62 (8)	11.01 ± 0.86 (8)	13.61 ± 1.04 (8)	8.29 ± 0.89 (8) *
Percent Monocytes	1.41 ± 0.09 (8)	1.99 ± 0.50 (8)	1.20 ± 0.23 (8)	1.28 ± 0.11 (8)	1.46 ± 0.17 (8)	1.46 ± 0.13 (8)	0.91 ± 0.18 (8) *
Percent Eosinophils	2.38 ± 0.30 (8)	1.70 ± 0.14 (8)	1.94 ± 0.29 (8)	2.58 ± 0.68 (8)	2.55 ± 0.77 (8)	1.75 ± 0.31 (8)	2.26 ± 0.84 (8)
Percent Basophils	0.59 ± 0.06 (8)	0.60 ± 0.16 (8)	0.61 ± 0.12 (8)	0.66 ± 0.09 (8)	0.53 ± 0.05 (8)	0.40 ± 0.05 (8)	0.44 ± 0.14 (8)
Percent Large Unstained Cells	1.25 ± 0.19 (8) *	0.88 ± 0.22 (8)	1.04 ± 0.23 (8)	1.00 ± 0.17 (8)	1.04 ± 0.29 (8)	0.70 ± 0.10 (8)	1.34 ± 0.38 (8)

Study Number: I10482

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Mouse/B6C3F1/N

M03: Peripheral Blood Leukocyte Cell Differential

Test Compound: N-Butylbenzenesulfonamide

CAS Number: 3622-84-2

Date Report Requested: 11/04/2020

Time Report Requested: 14:06:22

Lab: Burleson Research Technologies

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****